TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Digital Movement in the World of Inactive Children: Outcomes of Playing Active Video Games in a Pilot Randomized Trial
Brief Summary: Inactivity was reported to be high in children and considered to be the fourth common cause of death in all ages. The reason for children is usually the increasing indoor use of sedentary screen time. Active Video Games (AVG) have recently been introduced for decreasing the sedentary time for children and directing them to physical activity (PA) at home.The aim of this study is to show the quantitative effect of games on physical fitness parameters like weight, body mass index (BMI) and fat ratio (FR). The study also aims at the factors for motivation or continuance of the games as self-perception and enjoyment levels together with qualitative effects of games on satisfaction and attitude changes in inactive children.


Options:
A: Arm Label: garden intervention; Type: EXPERIMENTAL; Interventions: Behavioral: garden | Arm Label: no garden; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: garden; Assigned to Arm(s): garden intervention
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Active Video Games | Intervention Type: OTHER; Name: Active Video Games; Assigned to Arm(s): Intervention Group
C: Arm Label: A+PAAC; Type: EXPERIMENTAL; Interventions: Behavioral: A+PAAC | Arm Label: CON; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CON | Intervention Type: BEHAVIORAL; Name: A+PAAC; Assigned to Arm(s): A+PAAC | Intervention Type: BEHAVIORAL; Name: CON; Assigned to Arm(s): CON
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: School children and adolescents as health experts | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School children and adolescents as health experts; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
Brief Summary: This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.

Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.


Options:
A: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:
B: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Placebo
D: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
Brief Summary: This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.

Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
C: Arm Label: BCD-085 Q2W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q2W | Arm Label: BCD-085 Q4W; Type: EXPERIMENTAL; Interventions: Drug: BCD-085 Q4W | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCD-085 Q2W; Assigned to Arm(s): BCD-085 Q2W | Intervention Type: DRUG; Name: BCD-085 Q4W; Assigned to Arm(s): BCD-085 Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Health Literacy Activation Among the Chronic Obstructive Pulmonary Disease Patients and Designated Support Dyad
Brief Summary: This study investigates whether increasing health literacy among COPD patients and their designated health coach during a hospital admission caused by symptoms exacerbation will lead to better health outcomes including increased health quality, and lower healthcare utilization.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
C: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanochemical Ablation vs Thermal Ablation in Patients With Great Saphenous Vein Insufficiency
Brief Summary: Patients with GSV reflux were randomized to undergo either MOCA or thermal ablation with laser or radiofrequency. The main outcome measure was the occlusion rate of the GSV at one year.Patients with GSV reflux were randomized to undergo either MOCA or thermal ablation with laser or radiofrequency. The main outcome measure was the occlusion rate of the GSV at one and three years.


Options:
A: Arm Label: CE Marked Sapheon Closure System in GSV; Type: EXPERIMENTAL; Interventions: Device: CE Marked Sapheon Closure System | Intervention Type: DEVICE; Name: CE Marked Sapheon Closure System; Assigned to Arm(s): CE Marked Sapheon Closure System in GSV
B: Arm Label: RFA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency ablation (RFA) | Arm Label: MOCA; Type: EXPERIMENTAL; Interventions: Device: Mechanochemical Endovenous Ablation (MOCA) | Intervention Type: DEVICE; Name: Mechanochemical Endovenous Ablation (MOCA); Assigned to Arm(s): MOCA | Intervention Type: PROCEDURE; Name: Radiofrequency ablation (RFA); Assigned to Arm(s): RFA
C: Arm Label: MOCA; Type: EXPERIMENTAL; Interventions: Procedure: MOCA | Arm Label: EVLA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EVLA | Arm Label: RFA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RFA | Intervention Type: PROCEDURE; Name: MOCA; Assigned to Arm(s): MOCA | Intervention Type: PROCEDURE; Name: EVLA; Assigned to Arm(s): EVLA | Intervention Type: PROCEDURE; Name: RFA; Assigned to Arm(s): RFA
D: Arm Label: VenaSeal SCS; Type: EXPERIMENTAL; Interventions: Device: VenaSeal SCS | Arm Label: RFA (ClosureFast); Type: ACTIVE_COMPARATOR; Interventions: Device: ClosureFast Radiofrequency Ablation (RFA) | Arm Label: Roll-in (VenaSeal SCS); Type: EXPERIMENTAL; Interventions: Device: Roll-in (VenaSeal SCS) | Intervention Type: DEVICE; Name: VenaSeal SCS; Assigned to Arm(s): VenaSeal SCS | Intervention Type: DEVICE; Name: ClosureFast Radiofrequency Ablation (RFA); Assigned to Arm(s): RFA (ClosureFast) | Intervention Type: DEVICE; Name: Roll-in (VenaSeal SCS); Assigned to Arm(s): Roll-in (VenaSeal SCS)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of a Herbal Supplement in the Prevention of Treatment of Post-traumatic Stress Disorder Versus Placebo (PHYTéS Study)
Brief Summary: Psycho-traumatic disorders are a disabling condition whose epidemiological data vary according to the country but also the populations studied and the measuring instruments used. The estimated prevalence of posttraumatic stress disorder (PTSD) appeared to be increasing in recent years, and this appears to be due, among other things, to the improvement of the standardized evaluation procedure. The survey "Mental Health in General Population", conducted in metropolitan France between 1999 and 2003 on more than 36,000 people estimated its instantaneous prevalence (last month) of a full PTSD was 0.7% in the SMPG overall sample, with almost equal frequency between men (45%) and women (55%). This figure is close to that reported in a European population for the ESEMeD study. A very significant psychiatric comorbidity was found in subjects with PTSD, particularly with mood disorders, other anxiety disorders and addictive behaviors. The link with the suicidal risk was clearly established, which is the gravity of this pathology.

The most important publications are made by American teams who have identified and evaluated the treatment of this pathology among veterans of the various wars led by the country.


Options:
A: Arm Label: Treatment - prazosin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prazosin | Arm Label: Control - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Prazosin; Assigned to Arm(s): Treatment - prazosin | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Control - placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Dronabinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dronabinol | Intervention Type: DRUG; Name: Dronabinol; Assigned to Arm(s): Dronabinol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ALEOZEN group; Type: EXPERIMENTAL; Interventions: Drug: aleozen | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: aleozen; Assigned to Arm(s): ALEOZEN group | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): placebo group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing PharmacoTherapy In the Multimorbid Elderly in Primary CAre: a Cluster Randomized Controlled Trial (the OPTICA Trial)
Brief Summary: The objective of this randomized controlled trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), put into practice through the STRIP Assistant (STRIPA) and implemented by general practitioners (GPs), will lead to an improvement in clinical and economic outcomes in patients aged 65 or older with multimorbidity and polypharmacy.


Options:
A: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Other: tele-expertise | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: tele-expertise; Assigned to Arm(s): experimental group
B: Arm Label: STRIPA intervention; Type: EXPERIMENTAL; Interventions: Device: STRIPA intervention | Arm Label: Sham intervention; Type: SHAM_COMPARATOR; Interventions: Other: Sham intervention | Intervention Type: DEVICE; Name: STRIPA intervention; Assigned to Arm(s): STRIPA intervention | Intervention Type: OTHER; Name: Sham intervention; Assigned to Arm(s): Sham intervention
C: Arm Label: naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non-naive Deprescribing arm; Type: EXPERIMENTAL; Interventions: Other: Team-care deprescribing with deprescribing guide | Arm Label: non-naive Wait-list Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Team-care deprescribing with deprescribing guide; Assigned to Arm(s): naive Deprescribing arm, non-naive Deprescribing arm
D: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Pedometers for the Enhancement of Post Caesarean Mobility in High Risk Patients Using a Personalized Repeated Feedback Approach - a Randomized Controlled Trial
Brief Summary: This is a randomized controlled trial, planned to study the effects of pedometers (digital step counters) on patient mobility following cesarean delivery. The investigators plan to randomize patients at high risk for thromboembolic events to participants with a personalized repeated feedback approach based on pedometer results, versus participants with no feedback to pedometer results.


Options:
A: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
B: Arm Label: Bemiparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bemiparin, Drug: Enoxaparin | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): Bemiparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Bemiparin, Enoxaparin
C: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin
D: Arm Label: Feedback; Type: EXPERIMENTAL; Interventions: Other: personalized repeated feedback approach | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: personalized repeated feedback approach; Assigned to Arm(s): Feedback

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo
Brief Summary: This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.


Options:
A: Arm Label: Cipaglucosidase Alfa/Miglustat; Type: EXPERIMENTAL; Interventions: Biological: Cipaglucosidase Alfa, Drug: Miglustat | Arm Label: Alglucosidase Alfa/Placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: Alglucosidase Alfa, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Cipaglucosidase Alfa; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: BIOLOGICAL; Name: Alglucosidase Alfa; Assigned to Arm(s): Alglucosidase Alfa/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alglucosidase Alfa/Placebo
B: Arm Label: Albuterol; Type: EXPERIMENTAL; Interventions: Drug: Albuterol | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Albuterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator
C: Arm Label: avalglucosidase alfa (GZ402666); Type: EXPERIMENTAL; Interventions: Drug: Avalglucosidase alfa (GZ402666) | Arm Label: alglucosidase alfa (GZ419829); Type: ACTIVE_COMPARATOR; Interventions: Drug: Alglucosidase alfa (GZ419829) | Intervention Type: DRUG; Name: Avalglucosidase alfa (GZ402666); Assigned to Arm(s): avalglucosidase alfa (GZ402666) | Intervention Type: DRUG; Name: Alglucosidase alfa (GZ419829); Assigned to Arm(s): alglucosidase alfa (GZ419829)
D: Arm Label: alglucosidase alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): alglucosidase alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "Make my Day"- Incorporating Healthy Activity Patterns: A Person-centered, Digital Prevention Program to Support Health Among Persons at Risk for Stroke
Brief Summary: The purpose of this study is to evaluate the feasibility of a digital, person-centered stroke prevention program with a focus on primary prevention. The program is aiming to enable lifestyle change and to promote healthy activity patterns to decrease risk factors for stroke and in that way prevent future stroke.


Options:
A: Arm Label: Prevention treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention program for stroke | Arm Label: Standard treatment group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention program for stroke; Assigned to Arm(s): Prevention treatment group
B: Arm Label: Sitting; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting | Arm Label: Standing; Type: EXPERIMENTAL; Interventions: Behavioral: Standing | Arm Label: Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Walking | Intervention Type: BEHAVIORAL; Name: Sitting; Assigned to Arm(s): Sitting | Intervention Type: BEHAVIORAL; Name: Standing; Assigned to Arm(s): Standing | Intervention Type: BEHAVIORAL; Name: Walking; Assigned to Arm(s): Walking
C: Arm Label: FAST+SAM; Type: EXPERIMENTAL; Interventions: Behavioral: FAST+SAM | Arm Label: FAST alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: FAST alone | Arm Label: SAM alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SAM alone | Intervention Type: BEHAVIORAL; Name: FAST alone; Assigned to Arm(s): FAST alone | Intervention Type: BEHAVIORAL; Name: FAST+SAM; Assigned to Arm(s): FAST+SAM | Intervention Type: BEHAVIORAL; Name: SAM alone; Assigned to Arm(s): SAM alone
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Exercise | Arm Label: Arm 2; Type: OTHER; Interventions: Other: Stroke education | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Stroke education; Assigned to Arm(s): Arm 2

Answer: A